- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00553748
Phase I, Open Label, Single Center Safety Study of [F-18]FLT
July 1, 2008 updated by: Siemens Molecular Imaging
A Phase I, Open Label, Single Center Safety Study of [F-18]FLT
This is a ten subject, phase 1 study.
The purpose of the Phase 1 study is to demonstrate drug safety in a target group of subjects with high grade brain cancer.
This population represents a potential clinical population that may benefit from this PET imaging tracer.
The study will also begin collection of baseline imaging data and allow us to gain information to improve design and conduct of future trials.
Study Overview
Detailed Description
This is a ten subject, phase 1 study.
The purpose of the study is to demonstrate drug safety in a group with high grade brain tumors and to evaluate cell proliferation with F-18 FLT.
FLT is known to clear out of normal brain and detect brain tumor.
This population represents a potential clinical population that may benefit from this PET imaging tracer.
This information will help improve the design and conduct of future F-18 FLT clinical trials.
Study Type
Interventional
Enrollment (Actual)
11
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject may be male or female and of any race / ethnicity;
- At the time of study drug dosing, the subject has reached his or her 18th birthday;
- Subject has histologic diagnosis of one of the following malignancies - glioblastoma gliosarcoma, anaplastic mixed/anaplastic oligodendroglioma or (anaplastic) astrocytoma with lesion visible on CT or MR and minimum histological grade of III/IV;
- Subject with suspect radiation necrosis that are planned for re-section;
- Subject or subject's legally acceptable representative provides informed consent;
- Subject is capable of complying with study procedures and able to lie still in the PET scanner;
- Subject is capable of communicating with study personnel;
- Subject has adequate liver and kidney function
Exclusion Criteria:
- Subject is pregnant or nursing;
- Subject is anemic (as defined as a hemoglobin level <10);
- Subject has not received chemotherapy or radiation therapy within the two weeks prior to imaging.
- Subject has as reflected by a serum liver enzymes outside the normal laboratory reference range;
- Subject has a history of chronic liver disease, which may compromise liver function;
- Subject has kidney disease as reflected by a serum creatinine outside the normal laboratory reference range;
- Subject has prior history of stroke or other condition of the head or neck that, in the investigator's opinion, might affect circulation to the brain or image interpretation (examples include, but are not limited to, previous stroke with cystic softening and cerebral deformity, or arteriovenous malformation);
- Subject has a history of significant cerebrovascular disease;
- Subject has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete good quality data
- Subject has previously received [F-18]FLT at any time, or any other investigational product within the past two weeks.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: I
|
One - 10 mci dose of F-18 FLT is administered IV over about 5 seconds prior to PET imaging.
Each imaging dose contains no more than 6.1 micrograms of FLT.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety will be demonstrated through analysis of adverse events in subjects enrolled in the trial who received study drug
Time Frame: 24 hr
|
24 hr
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Charles M Intenzo, MD, Thomas Jefferson University Hospital, 132 S 10th St Phila, PA 19107
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2007
Primary Completion (Actual)
May 1, 2008
Study Completion (Actual)
May 1, 2008
Study Registration Dates
First Submitted
November 2, 2007
First Submitted That Met QC Criteria
November 2, 2007
First Posted (Estimate)
November 6, 2007
Study Record Updates
Last Update Posted (Estimate)
July 3, 2008
Last Update Submitted That Met QC Criteria
July 1, 2008
Last Verified
July 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D0008186
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...UnknownCancer | Metastatic Cancer | Metastatic Brain CancerChina
-
University of FloridaCompletedBrain Neoplasms | Brain Cancer | Brain Tumors | Seizure | Cancer of the Brain | Cancer of BrainUnited States
-
Eisai Inc.CompletedMetastatic Brain CancerUnited States
-
Australian & New Zealand Children's Haematology...Medical Research Future Fund; Minderoo Foundation; Children's Cancer Institute...RecruitingChildhood Cancer | Relapsed Cancer | Refractory Cancer | Childhood Leukemia | Childhood Solid Tumor | Childhood Brain TumorAustralia
-
InSightecActive, not recruitingGlioma | Metastatic Brain CancerCanada
-
Sunnybrook Health Sciences CentreActive, not recruitingBreast Cancer | Head and Neck Cancer | Gynecologic Cancer | Brain CancerCanada
-
Virginia Commonwealth UniversityUnited States Department of DefenseActive, not recruitingBrain Metastases, Adult | Cancer Metastatic to BrainUnited States
-
Stanford UniversityTerminatedCancer | Brain CancerUnited States
Clinical Trials on F-18 FLT
-
Siemens Molecular ImagingCompletedHead and Neck Cancer | Lung CancerUnited States
-
University of California, IrvineWithdrawnHead and Neck CancerUnited States
-
Dana-Farber Cancer InstituteBrigham and Women's HospitalCompletedEsophageal CancerUnited States
-
The Catholic University of KoreaUnknownNon-small Cell Lung CancerKorea, Republic of
-
AHS Cancer Control AlbertaCross Cancer InstituteTerminated
-
Frederick Daniel GrantDana-Farber Cancer InstituteCompleted
-
Marcelo F. Di Carli, MD, FACCGeneral Electric; Society of Nuclear Medicine and Molecular ImagingCompletedHigh Grade GliomaUnited States
-
Washington University School of MedicineRecruiting
-
University of Texas Southwestern Medical CenterCompletedPancreatic AdenocarcinomaUnited States
-
University of UtahTerminatedMalignant NeoplasmUnited States